CTLA4 and pneumonitis: The risk ratio (RR) was 1.79 [95% CI (0.83, 3.85); P = 0.14], suggesting a higher incidence of high-grade pneumonitis in patients treated with CTLA-4 inhibitors, though the difference was not statistically significant (Figure 7).